310 — Athena Heart

The treatment has been generally well-tolerated, with minor side effects like back pain or nausea reported during infusion. 🧬 Mechanism and Targets

As of early 2026, the program is advancing toward to further evaluate long-term outcomes and safety in larger patient populations. This technology represents a potential shift from chronic disease management to a "one-and-done" therapeutic model for heart health. ATHENA HEART 310

Targeted protein levels decreased by an average of 73%. The treatment has been generally well-tolerated, with minor

Mean reductions of ~49%, with peak effects reaching 87% . Targeted protein levels decreased by an average of 73%

ANGPTL3 is a protein that normally inhibits enzymes that clear lipids from the blood. By "turning off" this gene, the body can more effectively remove fats.

Recent data from clinical studies, including updates as of late 2025, show significant efficacy in participants: